MetaVia Inc. (MTVA)
MTVA trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | MTVA on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2016 |
| SEC CIK | 0001638287 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials
Not reported in SEC XBRL data.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "These conditions raise substantial doubt about our ability to continue as a going concern within one year from the issuance of these condensed consolidated financial statements." | 10-Q 2026-11-13 |
| Cash and burn | $12.6M cash; operating cash flow -$4.0M a quarter. | Report 2026-06-30 |
| Shares outstanding | 6,742,889 (2026-11-09); 24,214,788 a year earlier; 38,812,518 three years earlier. 1y figure adjusted for splits (1-for-11 overall); 3y figure adjusted for splits (1-for-88 overall). | Cover page 2026-11-09 |
| Reverse splits, 3 years | 2; latest 1-for-11 on 2025-12-05 | Source 2025-12-05 |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the market | Latest 2026-07-02 |
| Exchange deficiency notices, 12 months | 1 (8-K item 3.01) | 8-K 2025-11-26 |
| Auditor | BDO USA, P.C., Boston, Massachusetts, United States | PCAOB Form AP 2026-03-26 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2026 2026-06-30 | Not filed | -$5.3M | -$3.8M | $12.6M | No debt tags | Needs four quarters | 10-Q 2026-08-06 |
| Q1 2026 2026-03-31 | Not filed | -$3.8M | -$4.3M | $13.7M | No debt tags | Needs four quarters | 10-Q 2026-08-06 |
| Q4 2025 2025-12-31 | Not filed | -$1.9M | -$4.9M | $10.3M | No debt tags | Needs four quarters | 10-K 2026-03-26 |
| Q3 2025 2025-09-30 | Not filed | -$3.4M | -$3.0M | $14.3M | No debt tags | Needs four quarters | 10-Q 2025-11-06 |
| Q2 2025 2025-06-30 | Not filed | -$4.0M | -$3.1M | $17.6M | No debt tags | Needs four quarters | 10-Q 2026-08-06 |
| Q1 2025 2025-03-31 | Not filed | -$3.7M | -$4.8M | $11.2M | No debt tags | Needs four quarters | 10-Q 2026-08-06 |
| Q4 2024 2024-12-31 | Not filed | -$5.2M | -$5.5M | $16.0M | No debt tags | Needs four quarters | 10-K 2026-03-26 |
| Q3 2024 2024-09-30 | Not filed | -$5.7M | -$5.5M | $21.7M | No debt tags | Needs four quarters | 10-Q 2025-11-06 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-07-02 |
| Latest annual report | 10-K | 2026-03-26 |
| Latest quarterly / interim | 10-Q | 2026-11-13 |
| Latest current report | 8-K | 2026-11-16 |
| Latest proxy | DEF 14A | 2026-04-27 |
Source: SEC EDGAR submissions feed, 637 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -9.1% |
| 1 month | -9.1% |
| 3 months | -11.0% |
| Year to date | -84.6% |
| 1 year | -82.1% |
| From 52-week high | -88.7% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| CALC | CalciMedica Inc. | $1.19 | -1.65% | $8.2M |
| RKTO | Rocket One Inc. | $0.3210 | +0.03% | $8.0M |
| ENSC | Ensysce Biosciences Inc. | $0.4095 | -2.13% | $8.0M |
| VTGN | Vistagen Therapeutics Inc. | $0.1843 | +2.11% | $8.5M |
| MBRX | Moleculin Biotech Inc. | $7.14 | -9.28% | $7.6M |
| UPC | Universe Pharmaceuticals Inc. | $1.48 | -1.99% | $7.4M |
| PHIO | Phio Pharmaceuticals Corp. | $0.7522 | -2.44% | $9.0M |
| BFRG | Bullfrog AI Holdings Inc. | $0.4878 | -9.92% | $9.0M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier